ClinicalTrials.gg
CompletedNCT06028464Updated Nov 5, 2025Results posted

A Study in Healthy Men to Test Whether Carbamazepine Influences the Amount of Zongertinib in the Blood

A Phase 1 interventional study of Zongertinib and Carbamazepine in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-05.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

The main objective of this trial is to investigate the effect of multiple oral doses of the strong CYP3A inducer carbamazepine on the pharmacokinetics of a single dose of BI 1810631 in plasma.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male subjects according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (Blood Pressure (BP), Pulse rate (PR)), 12-lead (ECG), and clinical laboratory tests
  • Age of 18 to 55 years (inclusive)
  • (BMI) of 18.5 to 29.9 kg/m2 (inclusive)
  • Signed and dated written in accordance with ICH-GCP and local legislation prior to admission to the trial

Exclusion criteria

Exclusion Criteria:

  • Any finding in the medical examination (including BP, PR or , the neurological examination, or the skin inspection) deviating from normal and assessed as by the investigator
  • Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg, diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 50 to 90 bpm
  • Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
  • Any evidence of a concomitant disease assessed as clinically relevant by the investigator
  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  • Cholecystectomy or other surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy or simple hernia repair)
  • Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders
  • History of relevant orthostatic hypotension, fainting spells, or blackouts
  • Further exclusion criteria apply
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Zongertinib Alone (Reference)/ Zongertinib+Carbamazepine (Test)

    Participants took a single 60 mg oral dose of Zongertinib after fasting overnight (reference period). In the test period, they took the same Zongertinib dose after 18 days of daily Carbamazepine pretreatment, with doses increasing from 200 mg to 600 mg. They continued taking 600 mg of Carbamazepine daily for 6 days after the Zongertinib dose.

    Drug: Zongertinib · Drug: Carbamazepine

Interventions

  • Participants were administered a single dose of 60 milligrams (mg) of Zongertinib film-coated tablet orally on Day 1 with 240 milliliters (mL) of water after an overnight fast of at least 10 hours.

    Also known as: Hernexeos®

  • Participants received increasing doses of Carbamazepine once daily as extended-release tablets with 240 mL of water for 18 days, starting at 200 mg, then 400 mg, and finally 600 mg. Afterward, they continued taking 600 mg of Carbamazepine once daily for 6 days.

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-time Curve of Zongertinib in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)

    Area under the concentration-time curve of Zongertinib in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞). Geometric least square mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model.

    Time frame: One hour before administration of zongertinib, and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 11, 12, 24, 36, 48, 72, 120, and 168 hours after administration.

  2. Maximum Measured Concentration of Zongertinib in Plasma (Cmax)

    Maximum measured concentration of Zongertinib in plasma (Cmax). Geometric least square mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model.

    Time frame: One hour before administration of zongertinib, and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 11, 12, 24, 36, 48, 72, 120, and 168 hours after administration.

Secondary outcomes

  1. Area Under the Concentration-time Curve of Zongertinib in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

    Area under the concentration-time curve of Zongertinib in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz). Geometric least square mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model

    Time frame: One hour before administration of zongertinib, and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 11, 12, 24, 36, 48, 72, 120, and 168 hours after administration.

07

Results

Posted Nov 5, 2025

Participant flow

The trial was an open-label, two-treatment, two-period, fixed-sequence crossover trial in healthy male Participants comparing the test treatment (T) with the reference treatment (R). Treatment R consisted of one single oral dose of 60 mg zongertinib as a film-coated tablet alone. Treatment T consisted of one single oral dose of 60 mg zongertinib as a film-coated tablet with multiple oral doses of carbamazepine, titrated from 200 mg once daily (q.d.) to 400 mg q.d., then to 600 mg q.d.

Period 1: Reference Treatment Period (R)
Participant flow — Period 1: Reference Treatment Period (R)
MilestoneZongertinib Alone (Reference)/ Zongertinib+Carbamazepine (Test)
Started16
Completed16
Not completed0
Washout
Participant flow — Washout
MilestoneZongertinib Alone (Reference)/ Zongertinib+Carbamazepine (Test)
Started16
Completed15
Not completed1
Withdrew: Positive drug test.1
Period 2: Test Treatment Period (T)
Participant flow — Period 2: Test Treatment Period (T)
MilestoneZongertinib Alone (Reference)/ Zongertinib+Carbamazepine (Test)
Started15
Completed15
Not completed0

Outcome measures

PrimaryArea Under the Concentration-time Curve of Zongertinib in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)

Area under the concentration-time curve of Zongertinib in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞). Geometric least square mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model.

Time frame:
One hour before administration of zongertinib, and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 11, 12, 24, 36, 48, 72, 120, and 168 hours after administration.
Reported as:
Geometric mean · hour * nanomole / liter (h*nmol/L)
Area Under the Concentration-time Curve of Zongertinib in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)
hour * nanomole / liter (h*nmol/L)Zongertinib Alone (Reference, R)Zongertinib+Carbamazepine (Test, T)
Area Under the Concentration-time Curve of Zongertinib in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)12334.87 ± NA4500.05 ± NA
Statistical analysis
  • Zongertinib Alone (Reference, R) vs Zongertinib+Carbamazepine (Test, T) · Adjusted geometric mean ratio (%): 36.48 · 90% CI 31.96 to 41.64Ratio calculated as test/reference\*100. Intra-individual Geometric coefficient of variation \[%\] = 21.9
PrimaryMaximum Measured Concentration of Zongertinib in Plasma (Cmax)

Maximum measured concentration of Zongertinib in plasma (Cmax). Geometric least square mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model.

Time frame:
One hour before administration of zongertinib, and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 11, 12, 24, 36, 48, 72, 120, and 168 hours after administration.
Reported as:
Geometric mean · nanomole / liter (nmol/L)
Maximum Measured Concentration of Zongertinib in Plasma (Cmax)
nanomole / liter (nmol/L)Zongertinib Alone (Reference, R)Zongertinib+Carbamazepine (Test, T)
Maximum Measured Concentration of Zongertinib in Plasma (Cmax)914.01 ± NA515.84 ± NA
Statistical analysis
  • Zongertinib Alone (Reference, R) vs Zongertinib+Carbamazepine (Test, T) · Adjusted geometric mean ratio (%): 56.44 · 90% CI 45.11 to 70.60Ratio calculated as test/reference\*100. Intra-individual Geometric coefficient of variation \[%\] = 37.9.
SecondaryArea Under the Concentration-time Curve of Zongertinib in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

Area under the concentration-time curve of Zongertinib in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz). Geometric least square mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model

Time frame:
One hour before administration of zongertinib, and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 11, 12, 24, 36, 48, 72, 120, and 168 hours after administration.
Reported as:
Geometric mean · hour * nanomole / liter (h*nmol/L)
Area Under the Concentration-time Curve of Zongertinib in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)
hour * nanomole / liter (h*nmol/L)Zongertinib (BI 1810631) Alone (Reference, R)Zongertinib+Carbamazepine (Test, T)
Area Under the Concentration-time Curve of Zongertinib in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)12138.26 ± NA4430.05 ± NA
Statistical analysis
  • Zongertinib (BI 1810631) Alone (Reference, R) vs Zongertinib+Carbamazepine (Test, T) · Adjusted geometric mean ratio (%): 36.50 · 90% CI 31.91 to 41.74Ratio calculated as test/reference\*100. Intra-individual Geometric coefficient of variation \[%\] = 22.3.

Adverse events

Collected over AE collected: Zongertinib : Up to 14 days after the first Zongertinib administration. Zongertinib + Carbamazepine loading: From Day -18 to Day -12 in Period 2, 6 days. Carbamazepine loading: Carbamazepine loading: From Day -12 to Day 1 in Period 2 (second administration on zongertinib), 12 days. Zongertinib + Carbamazepine: Up to 14 days after the second Zongertinib administration. All cause-mortality: up to 48 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Zongertinib0/16 (0%)0/16 (0%)3/16 (18.8%)
Zongertinib+Carbamazepine Loading0/15 (0%)0/15 (0%)7/15 (46.7%)
Carbamazepine Loading0/15 (0%)0/15 (0%)11/15 (73.3%)
Zongertinib+Carbamazepine0/15 (0%)0/15 (0%)5/15 (33.3%)
Most frequent other events
Showing 10 of 26
Most frequent other events
EventZongertinibZongertinib+Carbamazepine LoadingCarbamazepine LoadingZongertinib+Carbamazepine
FatigueGeneral disorders1/163/154/150/15
ConstipationGastrointestinal disorders0/160/153/150/15
Back painMusculoskeletal and connective tissue disorders0/163/151/150/15
NasopharyngitisInfections and infestations1/160/150/152/15
Abdominal discomfortGastrointestinal disorders0/161/151/150/15
Abdominal pain upperGastrointestinal disorders0/161/150/150/15
DiarrhoeaGastrointestinal disorders0/160/151/150/15
Dry mouthGastrointestinal disorders0/161/150/150/15
Faeces hardGastrointestinal disorders0/160/151/150/15
FlatulenceGastrointestinal disorders0/161/150/150/15

Baseline characteristics

Treated set (TS): The treated set includes all participants who were treated with at least one dose of trial drug.

Age, Continuous
Age, Continuous(Years)Zongertinib Alone (Reference)/ Zongertinib+Carbamazepine (Test)
Mean41.5 ± 11.0
Sex: Female, Male
Sex: Female, Male(Participants)Zongertinib Alone (Reference)/ Zongertinib+Carbamazepine (Test)
Female0
Male16
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Zongertinib Alone (Reference)/ Zongertinib+Carbamazepine (Test)
Hispanic or Latino0
Not Hispanic or Latino16
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Zongertinib Alone (Reference)/ Zongertinib+Carbamazepine (Test)
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White16
More than one race0
Unknown or Not Reported0
08

Study locations

1 site
  • CRS Clinical Research Services Mannheim GmbH
    Mannheim, 68167, Germany
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.mystudywindow.com/msw/datatransparency

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2023 to primary completion in Dec 2023, 2 months.

Results were first posted in Nov 2025, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2023
First posted
Sep 8, 2023
StartActual
Sep 11, 2023
Primary completionActual
Dec 8, 2023
CompletionActual
Dec 8, 2023
Results first posted
Nov 5, 2025
Last update
Nov 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06028464
Responsible party
Sponsor
First posted
Sep 8, 2023
Start date
Sep 11, 2023
Primary completion
Dec 8, 2023
Completion
Dec 8, 2023
Results posted
Nov 5, 2025
Last update
Nov 5, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zongertinib

Start the discussion